What is King Pharmaceuticals's stock-based comp?

King Pharmaceuticals (KG) reported stock-based comp of $1.45M in Q1 2026.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

King Pharmaceuticals KG Stock-Based Comp

Stock-Based Comp at other companies

Arch Capital GroupACGL

$82M+10.8%

Everest GroupEG

$18M+200%

SiriusPointSPNT

$10.5M+38.2%

KKR & Co.KKR

$180.11M-1.9%

Skyward Specialty Insurance Group, Inc.SKWD

$2.99M+27.3%

Tiptree Inc.TIPT

——

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-71.3%

Enterprise value$184.93M-52.3%

P/E1.2×—

P/S1.6×-27.7×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's stock-based comp?: King Pharmaceuticals (KG) reported stock-based comp of $1.45M in Q1 2026.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.